Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Lactic acid

Also known as: lactic acid, AHA, alpha-hydroxy acid, ammonium lactate

Lactic acid is an alpha-hydroxy acid used at 5–12% in cosmetic products and from 10% to 92% as a professional peel. Lactate is also a genuine component of natural moisturising factor — which is a separate fact from what a free-acid peel does.

Evidence status

Moderate

The evidence splits three ways and practitioners should not treat it as one body. (1) Melasma: genuinely moderate — multiple randomised comparative trials plus a 2024 systematic review exist, but the findings are not flattering to lactic acid. The only randomised head-to-head against glycolic acid found glycolic significantly SUPERIOR (median MASI fall 2.85 vs 1.8, P=0.009), and the 2024 systematic review of 24 studies (n=1,075) concluded glycolic acid was the most safe and effective peel in melasma. Nearly all lactic acid melasma trials are small, single-centre, from India or Iraq, in Fitzpatrick III-V, with short follow-up. (2) Hydration/barrier: mechanistically coherent but manufacturer-dominated — the two foundational papers are authored entirely by Unilever Research and Kanebo Cosmetics staff respectively. (3) Penetration: the 'larger molecule, shallower penetration than glycolic' rationale is a physicochemical inference. No head-to-head penetration or peel-depth study comparing lactic and glycolic acid was found, and the principal hydroxy-acid review does not discuss molecular weight as a determinant of AHA penetration at all.

What lactic acid is, and the forms in use#

Lactic acid is an alpha-hydroxy acid — 2-hydroxypropanoic acid, molecular weight 90.08 g/mol against glycolic acid’s 76.05, a difference of a single CH2 group, and marginally less hydrophilic.[2]

The literature distinguishes three forms: L-lactic acid, D-lactic acid and the racemic D,L- mixture. The distinction is more than nomenclature, and the study that separated them is set out under barrier function below.[9]

Concentrations in professional use

Standard teaching references classify 10–30% as a light peel. The published melasma trials used 80%, 90% and 92%, with the original protocol specifying pure lactic acid at 92% and pH 3.5.[1, 3, 5, 6]

Two quite different procedures therefore share one name. A 92% free-acid peel at pH 3.5 is a keratocoagulant intervention; a 20% peel is not.

Lactic acid within Jessner’s solution

Jessner’s solution contains 14% lactic acid, alongside 14% resorcinol and 14% salicylic acid, in ethanol.[1]The combination itself, and the protocol for using it, are treated in the Jessner’s peel entry.

Use of lactic acid in aesthetic practice#

Licensing and scope attach to the procedure, its depth, the premises and the jurisdiction rather than to the molecule — it is those, and not the choice of acid, that determine what you may perform. The canonical treatment sits in the chemical-peel entry; what follows is the position as it stands for a lactic acid peel.[16]

No licensing scheme for non-surgical cosmetic procedures is in force in England. The green/amber/red three-tier model remains a proposal requiring secondary legislation, and the consultation response of 7 August 2025 states that further work is required to determine where specific procedures will sit.[16]

One proposal detail bears directly on lactic acid: chemical peels were proposed to “sit across different categories” according to strength and depth of penetration, so a 10–30% lactic acid peel and a 92% lactic acid peel could in principle fall into different tiers. No such assignment has been made.[16]i

In voluntary regulation, lactic acid peels sit under the JCCP/CPSA modality “Skin Rejuvenation — Micro Needling and Peels”, one of five recognised modalities. JCCP registration carries no legal force.[17]

Contraindications and cautions#

Screening, contraindication and depth-related risk in chemical peeling are properties of the procedure rather than of the acid, and are treated in the chemical-peel entry. Two cautions are specific to lactic acid: the populations its evidence was gathered in, and the basis for the photoprotection advice that follows a peel.

Fitzpatrick phototype and the published populations

The lactic acid melasma trials were conducted almost entirely in Fitzpatrick III–V populations in Iraq and India. The foundational study was restricted to skin type IV with epidermal melasma confirmed on Wood’s light in every patient; the split-face study describes its patients only as “mostly” type IV with “mostly” epidermal melasma.[3, 4, 5]

Lactic acid is widely promoted as the peel of choice for higher phototypes. It does not appear in any pooled comparison in the one meta-analysis dedicated to chemical peels for melasma in dark-skinned patients — 13 studies, 478 patients.[14]

The working consequence is that selection at the top of the scale rests on transfer from III–V rather than on evidence gathered there, and that expectation-setting should carry the same weight as the evidence behind it.

Photoprotection after treatment

The photosensitising finding in this area is for glycolicacid at 10%, in 14 subjects of Fitzpatrick II–III, described by its own authors as a small effect — and the same review notes that all such studies were done in types I–III and that cohorts of IV–VI are still needed.[15]

No lactic acid photosensitivity study was found among the sources reviewed here, which is the result of a search rather than proof that none exists.[no source found] Photoprotection after a lactic acid peel therefore rests on extrapolation rather than on a direct finding, and is worth describing to a client as such.

Clinical uses and the evidence behind them#

Melasma

This is the indication lactic acid is most often chosen for and the one with the most comparative evidence behind it. The original evidence is open-label and uncontrolled: 20 patients enrolled, only 12 completing, all Fitzpatrick IV with epidermal melasma, treated with 92% lactic acid at pH 3.5 every three weeks for up to six sessions, with statistically significant MASI improvement and no side effects recorded.[3]

Against Jessner’s solution it held its position: in a 30-patient split-face comparison (24 completing), 92% lactic acid was as effective as Jessner’s on the other side, both with significant MASI improvement and no side effects — though side allocation was fixed rather than randomised and no blinding was described.[4]

Against pyruvic acid it was slightly but not significantly better: mean MASI fell 55.4% against 52.1%, both peels safe with only mild burning — though both arms were primed with 0.025% tretinoin for two weeks beforehand.[6]

Against glycolic acid it was outperformed. In the only randomised head-to-head found, 50% glycolic acid produced a significantly greater median MASI reduction than 80% lactic acid— 2.85 against 1.8, P = 0.009, across four sessions at two-week intervals in Fitzpatrick III–V patients.[5] A 2024 systematic review of 24 studies and 1,075 patients concluded that glycolic acid was the most safe and effective peeling agent in melasma, though heterogeneity prevented meta-analysis, so that ranking is a qualitative judgement rather than a pooled estimate.[13]

Taken together, the comparative evidence in melasma points to glycolic acid — from one small trial at non-equivalent strengths, 50% glycolic against 80% lactic, and one synthesis that could not pool its data. That is a direction of evidence rather than a treatment rule.

Periorbital melanosis

In a 70-patient randomised comparison, 30% lactic acid produced significantly greater pigment reduction than 30% mandelic acid (P = 0.001) with higher patient satisfaction (100% against 83.9%, P = 0.011), irritation more frequent in the mandelic arm, and the authors concluding lactic acid may suit sensitive skin.[7]

The indication is periorbital melanosis rather than melasma, and the result does not transfer between them.

Photoageing

In one 1996 study, 12% lactic acid twice daily for three months was associated with epidermal anddermal changes — firmness and thickness, with clinical improvement in smoothness, lines and wrinkles — whereas 5% was associated with surface and epidermal changes only.[8]

The record behind that comparison is thin. It gives no sample size, no randomisation or blinding, no vehicle or untreated arm and no numerical effect sizes, and it compares 5% against 12%, not against untreated skin.[8] A two-concentration comparison on that basis does not establish 12% as a clinical threshold, which is the use the figure is most often put to.

Barrier function and hydration

Lactate is a genuine, measurable component of natural moisturising factor in human stratum corneum, not merely a marketing description: it is significantly depleted in mild atopic dermatitis skin, alongside PCA, urea, sodium and potassium.[10] There is partial human support for the humectant role, in that topical potassium lactate was the only depleted NMF component that measurably increased skin surface hydration when reapplied in atopic dermatitis skin.[10]

In a leave-on lotion study, L-lactic acid produced a 48% rise in stratum corneum ceramides, D,L-lactic acid 25%, and D-lactic acid no measured increase; barrier improvement and resistance to xerosis followed L- and D,L- but not D-.[9]

That study was authored by a manufacturer and reports neither its sample size nor its lotion concentrations, and its endpoint was stratum corneum ceramide and barrier response rather than product performance. All of this evidence concerns leave-on products and neutralised salts at physiological or cosmetic levels.

Selecting lactic acid#

Selection turns on the indication, and strength follows the indication rather than the reverse — the melasma protocols were conducted at 80–92%, and the periorbital melanosis result at 30%.

Two results support a positive selection. The first is periorbital melanosis, where 30% lactic acid produced significantly greater pigment reduction than 30% mandelic acid, with higher patient satisfaction and irritation more frequent in the mandelic arm.[7] It is the only comparative result reviewed here obtained at a strength within the light-peel range.

The second is barrier support from a leave-on product, where the evidence favours the L-isomer: a 48% rise in stratum corneum ceramides against no measured increase for D-lactic acid.[9] That is a choice between finished products rather than between acids.

Tolerability relative to glycolic acid

Most of the category’s positioning rests on this comparison. In the head-to-head trial, 4 of 18 glycolic acid patients had adverse effects — two erythema, one frosting, one post-inflammatory hyperpigmentation — against 0 of 16 in the lactic acid arm. The difference was not statistically significant (P = 0.105), and the trial was underpowered for safety.[5]

Directionally supported and not established is the honest description: a reasonable expectation to hold, and not a claim the evidence will carry.

The isomer on the label

The ceramide result makes the isomer a variable in its own right, alongside concentration, and one that professional product labelling rarely discloses. The finding does not establish that the isomer matters more than the concentration, or that it carries over to a professional peel — the endpoint was stratum corneum ceramide and barrier response in a leave-on lotion.[9]

Adverse effects and their management#

Effects recorded in the published trials

The adverse effects recorded in the published trials were few and mild. No side effects were recorded in either 92% melasma series.[3][4] Mild burning was reported in the 90% comparison against pyruvic acid.[6] The lactic acid arm of the glycolic head-to-head recorded none at 80%, in a trial its authors described as underpowered for safety.[5]

Those denominators are small and the follow-up short. The record is better read as an absence of recorded harm in small trials than as a demonstrated safety margin, particularly at the concentrations those trials used.

Reducing, stopping and referring

Management of a peel reaction, and the decision to reduce, stop or refer, are properties of the procedure rather than of the acid, and are treated in the chemical-peel entry. None of the lactic acid sources reviewed here sets a stop threshold or a referral trigger of its own, so the procedural thresholds are the operative ones at every concentration.

Referral and scope boundaries#

Two boundaries sit around a lactic acid peel, and neither of them is set by the acid.

  • The diagnosis. Melasma, periorbital melanosis and post-inflammatory hyperpigmentation are separate conditions with separate evidence, and every trial reviewed here recruited patients whose diagnosis had already been established. Assessment is treated in the melasma entry.
  • The procedure. Depth, technique, aftercare and complication management belong to the peel rather than to the acid, and are treated in the chemical-peel entry.

Mechanism of action#

Two mechanisms have been proposed for lactic acid beyond desquamation, and both rest on cell-culture work. The first is that lactic acid stimulates keratinocyte ceramide biosynthesis, with L-lactic acid producing a 300% increase against 100% for the D isomer — in-vitro keratinocyte work, and a proposed explanation for the stratum corneum finding rather than a demonstrated in-vivo pathway.[9]i

The second is a direct action on pigment: lactic acid inhibits tyrosinase enzyme activity independently of its acidity. That was shown only in mouse and human melanoma cell lines, where glycolic acid inhibited melanin formation in a similar dose-dependent manner, so it offers no basis for preferring one acid over the other on pigment.[12]i

The endogenous side is separate again. Stratum corneum lactate is concentrated in the surface layers and is largely supplied from outsidethe corneocyte — from sweat — unlike filaggrin-derived free amino acids and PCA.[10]

Commonly misstated claims#

Four statements circulate widely in the trade. Each is set out below with what the primary literature was found to support.

“Lactic acid is a bigger molecule, so it penetrates less deeply.”

The molecular weights are real — 90.08 g/mol against 76.05.[2] The inference drawn from them has not been measured: no comparison of skin penetration depth, stratum corneum uptake or histological peel depth between lactic and glycolic acid at matched concentration or pH was found among the sources reviewed here.[no source found] The principal review of hydroxy-acid mechanisms does not discuss molecular weight as a determinant of AHA penetration at all, and offers no glycolic-versus-lactic comparison; the only penetration mechanism it addresses is lipophilicity, and that for a beta-hydroxy acid derivative.[15]

Supported statement: lactic acid is the larger molecule, and the penetration difference inferred from that has never been measured.

“Jessner’s solution is a lactic acid peel.”

It contains 14% lactic acid, and equally 14% salicylic acid and 14% resorcinol. Results attributed to Jessner’s — including its superiority over hydroquinone in melasma in darker skin (mean MASI difference −3.20, 95% CI −5.35 to −1.05, P = 0.004) — cannot be attributed to its lactic acid content.[1, 14]i

Supported statement:Jessner’s solution contains lactic acid, and its results are the results of a three-active formulation.

“Lactic acid is a humectant, so it hydrates.”

The NMF role is genuine. What has not been shown is hydration from lactate as a standalone agent: in a vehicle-controlled, randomised-order, within-subject study on the forearms of 20 healthy subjects, 5% urea and both urea/ammonium-lactate combinations produced significant stratum corneum hydration and improved barrier function, with no significant difference between the three, and 5% ammonium lactate alone was not among the treatments reported to achieve either. The authors do not state that it failed, so this is an absence in the reported results rather than a demonstrated negative, and the agent was ammonium lactate, the neutralised salt, rather than free lactic acid.[11]

Supported statement: lactate is a measurable NMF component, and the hydration evidence concerns neutralised salts in leave-on products rather than free acid at peel strength.

“Lactic acid is evidence-based for melasma.”

The melasma evidence was gathered at 80%, 90% and 92%, the original protocol at 92% and pH 3.5, while standard teaching references classify 10–30% as a light peel.[1, 3, 5, 6] A 92% free-acid peel at pH 3.5 and a 20% peel share a name and little else, so the trial evidence for one does not describe the other.

Supported statement:lactic acid has comparative trial evidence in melasma at 80–92%, and a light peel at 10–30% is not the procedure those trials tested.

Areas of remaining uncertainty#

  • Whether lactic acid penetrates less deeply than glycolic acid at all. No comparative study was found, which leaves depth unavailable as a basis for selection.
  • Whether it is genuinely gentler. Directionally supported and not statistically shown in an underpowered trial, which makes tolerability a reasonable expectation rather than a claim.
  • Whether the isomer effect on ceramides translates into clinical benefit from a peel rather than a leave-on product. Until it does, the isomer is a leave-on variable.
  • Anything specific to Fitzpatrick V–VI. The published work is concentrated in III–V and lactic acid is absent from the dark-skin meta-analysis, so practice at the top of the scale rests on transfer.
  • Photosensitivity after lactic acid, for which no study was found. Photoprotection advice is therefore extrapolated from glycolic acid.
  • The photoageing evidence base, whose sample size, control arm and blinding could not be verified — which is why 12% is not a validated threshold.

Frequently asked questions#

Lactic acid or glycolic acid for a client with melasma?

The comparative evidence points to glycolic acid, and it is thinner than that sentence sounds. One small randomised head-to-head found greater MASI reduction with 50% glycolic than 80% lactic— non-equivalent strengths — without a significant tolerability difference, and a 2024 synthesis favoured glycolic qualitatively without being able to pool the data.[13] That is a direction rather than a rule; assessment sits in the melasma entry and procedural safety in the chemical-peel entry.

Does the isomer matter?

On one leave-on lotion study, materially: a 48% rise in stratum corneum ceramides with L-lactic acid and no measured increase with D-. The study was manufacturer-authored and reports neither its sample size nor its lotion concentration, and professional products rarely state which isomer they contain.[9]

What photoprotection applies after a lactic acid peel?

The same as after any AHA, on extrapolated grounds. The photosensitivity data are for 10% glycolic acid in Fitzpatrick II–III subjects, and no lactic acid study was found.[15]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Samargandy S, Raggio BS. Chemical Peels for Skin Resurfacing. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; last updated 29 October 2023. Bookshelf ID NBK547752.Tier 4Supports: Source of the Jessner's solution formula, verbatim: "This solution is a mixture of 14% resorcinol, 14% salicylic acid, and 14% lactic acid dissolved in ethanol." Also classifies lactic acid as an alpha hydroxy acid derived from milk, describes it as a keratolytic available in concentrations of 10% to 30%, and places "10% to 30% lactic acid" in the light (superficial) peel category. SCOPE LIMIT: this is a tertiary teaching reference, not primary data. It does NOT specify lactic acid's penetration depth relative to other AHAs and provides NO targeted guidance on lactic acid in Fitzpatrick III-VI; it only recommends general caution with all peeling agents in darker skin because of dyschromia risk.Funding / interest: No commercial funding declared; StatPearls is a subscription medical education publisher.
  2. PubChem Compound Summary. Lactic acid, CID 612; Glycolic acid, CID 757. National Center for Biotechnology Information, US National Library of Medicine. Accessed 1 August 2026.Tier 4Supports: Retrieved directly from the PubChem REST API. Lactic acid: CID 612, molecular formula C3H6O3, molecular weight 90.08 g/mol, IUPAC name 2-hydroxypropanoic acid, XLogP -0.7. Glycolic acid: CID 757, molecular formula C2H4O3, molecular weight 76.05 g/mol, IUPAC name 2-hydroxyacetic acid, XLogP -1.1. This establishes that lactic acid is the larger molecule (90.08 vs 76.05 g/mol, a difference of one CH2 group) and is marginally less hydrophilic (XLogP -0.7 vs -1.1). SCOPE LIMIT: this is physicochemical reference data only. It says NOTHING about skin penetration depth, clinical potency or tolerability, and cannot on its own support any penetration claim.
  3. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid as a new therapeutic peeling agent in melasma. Dermatol Surg. 2005 Feb;31(2):149-54; discussion 154. PMID 15762205.Tier 3Supports: The original lactic acid melasma study. Open-label, uncontrolled, single-arm case series at Baghdad Teaching Hospital, April 2001-August 2002. Twenty patients enrolled (18 female, 2 male; age 24-38, mean 29 +/- 4.264 SD). Agent: "Pure lactic acid, full strength (92%; pH 3.5)". Sessions every 3 weeks until desired response, maximum six sessions; follow-up 6 months after last session. Assessment by Melasma Area Severity Index (MASI) and Wood's light. ALL patients were skin type IV. Morphology: mask-like 7 (35%), butterfly 9 (45%), horseshoe 4 (20%). RESULTS: "Eight patients defaulted from the study after the first session for unknown reasons" — only 12 of 20 completed (40% attrition). Sessions ranged two to six. Wood's light showed increased contrast in all, i.e. epidermal melasma. "All 12 patients showed marked improvement, as calculated by the MASI score before and after treatment, and the response was highly statistically significant. No side effect was recorded in all treated patients." SCOPE LIMITS: no control arm, no randomisation, no blinding, 40% dropout, single skin type (IV only), epidermal melasma only, and the abstract reports NO numerical MASI values or percentage reduction.Funding / interest: No funding or conflict statement in the PubMed record. University of Baghdad academic authors; no declared commercial interest.
  4. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner's solution chemical peels. Dermatol Surg. 2006 Dec;32(12):1429-36. PMID 17199649.Tier 3Supports: Split-face comparative study, same Baghdad centre and same period (April 2001-August 2002). Thirty patients enrolled, "mostly of skin type IV according to Fitzpatrick's classification", 26 women (86.67%), 4 men (13.33%), age 18-50 (mean +/- SD 33.53 +/- 6.96 years). Design: "Pure lactic acid full strength (92%, pH 3.5) was used as a new peeling agent on the left side of the face while Jessner's solution was applied to the right side of the face." Sessions every 3 weeks until desired response; 6-month follow-up. RESULTS: six defaulted after the first session; 24 completed. Number of sessions 2 to 5. Wood's light showed mostly epidermal melasma. "All patients showed marked improvement as calculated by MASI score before and after treatment, and the response was highly statistically significant. No side effect was recorded in all treated patients." CONCLUSION verbatim: lactic acid "was as effective as Jessner's solution." SCOPE LIMITS: side allocation to left/right was fixed rather than randomised, no blinding stated, 20% dropout, predominantly skin type IV, epidermal melasma, and again NO numerical MASI values in the abstract. Note the important internal comparison: this is lactic acid 92% versus a solution that itself contains 14% lactic acid alongside 14% salicylic acid and 14% resorcinol.Funding / interest: No funding or conflict statement in the PubMed record. University of Baghdad academic authors.
  5. Kadu PP, Laul RA. 80% Lactic Acid Peel Versus 50% Glycolic Acid Peel for Melasma: A Randomised Clinical Trial. Indian J Dermatol. 2025 May-Jun;70(3):152-156. PMID 40487492; PMCID PMC12139622.Tier 2Supports: THE MOST DIRECTLY DECISIVE SOURCE for the lactic-versus-glycolic question. Prospective, single-blinded (study subjects), randomised trial, Government Medical College, Akola, Central India. Forty patients aged 18-50 randomised 20/20 to 80% lactic acid or 50% glycolic acid, four sessions at 2-week intervals; MASI at baseline and 10 weeks; Mann-Whitney test. Thirty-four completed (18 glycolic, 16 lactic); six lost to follow-up. "All the patients belonged to Fitzpatrick skin phototypes III, IV, and V." EFFICACY: median (25th-75th percentile) MASI decrease with glycolic 50% was 2.85 (1.875-3) versus lactic 80% at 1.8 (1.125-2.4), P = 0.009 — glycolic SIGNIFICANTLY SUPERIOR. MASI values: glycolic baseline 8.2 (6-12.6) to 5.4 (3.6-9.6); lactic baseline 8.65 (5.325-14.025) to 7.1 (3.6-11.4). TOLERABILITY (the crux of the 'gentler' claim): glycolic arm 4 of 18 had adverse effects — 2 erythema, 1 frosting, 1 post-inflammatory hyperpigmentation; lactic arm 0 of 16 reported any adverse effect. BUT: "The difference between the side effects, however, was not statistically significant (P value 0.105)." Authors' conclusion: "50% glycolic acid peel is more efficacious than 80% lactic acid peel for the treatment of melasma." STATED LIMITATIONS: small sample size; failure to evaluate melasma depth (epidermal, dermal or mixed) or relate efficacy to lesion depth. Also note the concentrations are not equipotent — 80% lactic versus 50% glycolic is not a like-for-like molar comparison.Funding / interest: "Funding Statement: Nil" and "There are no conflicts of interest."
  6. Goyal S, Brar BK, Kumar S, Boparai A, Hundal S, Mehta A. Comparative Evaluation of Therapeutic Efficacy and Safety of 90% Lactic Acid Peel Versus 40% Pyruvic Acid Peel in Epidermal Melasma. Indian Dermatol Online J. 2025 Jun 17;16(4):564-570. PMID 40688117; PMCID PMC12270427.Tier 2Supports: Randomised comparative trial, Guru Gobind Singh Medical College, Faridkot, Punjab. Sixty patients randomised to two groups of 30. IMPORTANT PRACTICE DETAIL: "Priming was done by 0.025% tretinoin cream daily for 2 weeks prior to the peeling" — the lactic acid arm was primed, not peeled cold. Group A: 90% lactic acid every 2 weeks; Group B: 40% pyruvic acid every 2 weeks, for 12 weeks. Mean age 33.57 (A) and 33.36 (B). Centrofacial pattern in 56.7% (A) and 63.33% (B). RESULTS: mean MASI fell 10.42 to 4.59 in the lactic arm and 9.65 to 4.53 in the pyruvic arm; at 24 weeks percentage reduction was 55.44% (lactic) versus 52.07% (pyruvic). MELASQoL fell from 36.83 to 21.30 (lactic) and 37.70 to 20.10 (pyruvic). CONCLUSION verbatim: "lactic acid 90% peel showed slightly better results compared to pyruvic acid 40% peel, though not statistically significant. Both peels were safe. Mild burning sensation was reported by a few patients." SCOPE LIMITS: authors state "Small sample size"; epidermal melasma only; no glycolic acid comparator; no untreated or vehicle control, so the tretinoin priming and natural history cannot be separated from the peel effect. Fitzpatrick types not reported in the abstract, though the Punjab population is predominantly III-V.Funding / interest: "There are no conflicts of interest."
  7. Malviya A, Shrivastava S, Pancholi S, Hassanandani T, Kumar V, Dhakad JS. A Prospective Study Comparing Clinical Efficacy of 30% Mandelic Acid Peel Versus 30% Lactic Acid Peel in Periorbital Melanosis. Indian Dermatol Online J. 2025 Nov 1;16(6):916-920. PMID 41051381; PMCID PMC12622926.Tier 2Supports: Included for BALANCE — this is the trial where lactic acid wins, and at a realistic professional concentration rather than 80-92%. Prospective comparative study, tertiary institute, 18 months (September 2022-February 2024), 70 patients randomly assigned to 30% mandelic acid (35) or 30% lactic acid (35), three sessions at weeks 0, 2 and 4, end-of-study visit week 6. Outcomes: periorbital melanosis grading, visual analogue scale, patient satisfaction, adverse events. RESULTS: both improved significantly, but "the lactic acid group exhibited a significantly greater reduction in pigmentation (50% of patients with more than 30% improvement in VAS, P = 0.001)". Patient satisfaction 100% (lactic) versus 83.9% (mandelic), P = 0.011. Side effects were mild erythema and swelling in both, with "exfoliation more common in the lactic acid group and irritation more frequent in the mandelic acid group". Authors conclude "lactic acid may be better for sensitive skin due to milder side effects". SCOPE LIMITS: the indication is periorbital melanosis (dark circles), NOT melasma — do not transfer the result. Authors state the study "is limited by its small sample size and short duration, which may impact the generalizability and long-term evaluation of the treatments". The comparator is mandelic acid, not glycolic acid, so this does not resolve the lactic-versus-glycolic gentleness question.Funding / interest: "There are no conflicts of interest."
  8. Smith WP. Epidermal and dermal effects of topical lactic acid. J Am Acad Dermatol. 1996 Sep;35(3 Pt 1):388-91. PMID 8784274.Tier 3Supports: The most-cited source for lactic acid in photoageing, and the origin of the 5%-versus-12% distinction used throughout cosmetic practice. Participants applied either 5% or 12% lactic acid twice a day for 3 months. Outcomes measured: skin smoothness and texture, depth and number of lines and wrinkles, and epidermal and dermal firmness and thickness. RESULTS verbatim: "Treatment with 12% lactic acid resulted in increased epidermal and dermal firmness and thickness and clinical improvement in skin smoothness and in the appearance of lines and wrinkles. No dermal changes were observed after treatment with 5% lactic acid; however, similar clinical and epidermal changes were noted." Conclusion: "Although 5% lactic acid modulates surface and epidermal changes, 12% lactic acid influences both the epidermis and the dermis." IMPORTANT SCOPE LIMITS, stated honestly: the abstract does NOT report the number of subjects, does not describe randomisation or blinding, and does not describe a vehicle or placebo control arm — the comparison is 5% against 12%, not against untreated skin. No numerical effect sizes are given for any outcome. I attempted to retrieve the full text via the publisher and received HTTP 403, so these design details could not be verified beyond the abstract. Treat the dose-response conclusion as suggestive rather than established.Funding / interest: No affiliation, funding or conflict-of-interest statement appears in the PubMed record, and the full text was not accessible to verify. Single-author paper. Commercial sponsorship can neither be confirmed nor excluded — a genuine gap, noted because much AHA cosmetic-efficacy work of this era was industry-conducted.
  9. Rawlings AV, Davies A, Carlomusto M, Pillai S, Zhang K, Kosturko R, Verdejo P, Feinberg C, Nguyen L, Chandar P. Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function. Arch Dermatol Res. 1996 Jun;288(7):383-90. PMID 8818186.Tier 3Supports: The mechanistic basis for the barrier/moisturisation claim, combining in-vitro and in-vivo human work — the two must not be conflated. IN VITRO: "lactic acid enhanced the production of ceramides by keratinocytes. L-Lactic acid was more effective than the D isomer (300% increase vs 100% increase)." Carbon label from lactic acid was incorporated into all keratinocyte lipid species, with greater incorporation into ceramides from L-lactate. IN VIVO (human): lotions containing L-lactic acid produced the greatest rise in stratum corneum ceramides (48% increase), followed by D,L-lactic acid (25% increase), while "D-lactic acid had no effect on stratum corneum ceramide levels." These ceramide increases "led to improvements in stratum corneum barrier function, measured by transepidermal water loss following a challenge to the skin with SLS and in the regression phase of a moisturization efficacy study. Significant improvements in barrier function and resistance to the appearance of skin xerosis were observed following L-lactic acid and D,L-lactic acid, but not following D-lactic acid treatment." PRACTICE-RELEVANT: isomer identity matters, and most cosmetic lactic acid is racemic D,L, which performed at roughly half the ceramide effect of pure L. SCOPE LIMITS: leave-on lotion concentrations, not peel concentrations; xerosis/barrier endpoints, not photoageing or pigmentation; sample sizes and lotion concentrations not given in the abstract; no comparison against glycolic acid.Funding / interest: MAJOR COMMERCIAL INTEREST: all ten authors are affiliated to Unilever Research, Edgewater Laboratory, NJ. Unilever manufactures and markets lactic-acid-containing moisturisers, and the paper's conclusion directly supports a product claim (L-lactic acid superiority). Weight accordingly.
  10. Sugawara T, Kikuchi K, Tagami H, Aiba S, Sakai S. Decreased lactate and potassium levels in natural moisturizing factor from the stratum corneum of mild atopic dermatitis patients are involved with the reduced hydration state. J Dermatol Sci. 2012 May;66(2):154-9. PMID 22464763.Tier 3Supports: The best available human evidence that lactate genuinely functions as a natural moisturising factor component rather than this being marketing shorthand. NMF components were extracted from three sequential tape-stripped stratum corneum samples from the volar forearm in healthy subjects and mild adult atopic dermatitis patients. RESULTS: "although FAAs levels were not remarkably reduced, levels of pyrrolidone carboxylic acid (PCA), lactate, urea, sodium and potassium were significantly decreased in NMF from mild AD skin. Among those components, only the topical application of potassium lactate effectively increased skin surface hydration indicating that reductions of lactate and potassium influence dry skin in mild AD patients." DISTRIBUTION FINDING with real mechanistic significance: "Unlike the distribution of filaggrin-derived FAAs and PCA, lactate, urea, potassium and sodium were abundant in the surface layer of the SC compared with the inner layer of the SC. Such findings strongly suggest that those components are supplied from outside the SC, i.e. they originate from sweat." So endogenous stratum corneum lactate is largely SWEAT-derived, not filaggrin-derived — a correction to the common teaching that NMF is simply a filaggrin breakdown product. SCOPE LIMITS: population is mild atopic dermatitis versus healthy controls, not photoageing or cosmetic dryness; sample size not stated in the abstract; the agent tested topically was potassium lactate, not free lactic acid at cosmetic pH.Funding / interest: COMMERCIAL INTEREST: lead author affiliated to the Innovative Beauty Science Laboratory, Kanebo Cosmetics Inc., Odawara, Japan — a cosmetics manufacturer with a direct interest in NMF-based moisturisation claims. Co-authors are from Tohoku University.
  11. Gloor M, Fluhr J, Lehmann L, Gehring W, Thieroff-Ekerdt R. Do urea/ammonium lactate combinations achieve better skin protection and hydration than either component alone? Skin Pharmacol Appl Skin Physiol. 2002 Jan-Feb;15(1):35-43. PMID 11803256.Tier 2Supports: An important CORRECTIVE to the assumption that lactic acid reliably hydrates as a standalone humectant. Twenty subjects with healthy skin, six randomised-order test areas on the forearms plus one untreated area, treated two weeks with: drug-free W/O vehicle; 5% ammonium lactate in W/O vehicle; 5% urea in W/O vehicle; 3% ammonium lactate + 3% urea; 5% ammonium lactate + 5% urea. Repetitive washings were added in the second week. Measures: TEWL, stratum corneum water content by corneometry (electrical capacitance), and cutaneous blood flow by laser Doppler, at baseline, day 7 and day 14. RESULT verbatim: "5% urea and both ammonium lactate/urea combinations produced significant stratum corneum hydration and improved stratum corneum barrier function; there were no significant differences between these three treatments." NOTE WHAT IS ABSENT: 5% ammonium lactate ALONE is conspicuously not among the treatments that achieved significant hydration and barrier improvement. This is a vehicle-controlled, within-subject, randomised-order design — methodologically stronger than most lactic acid cosmetic studies. SCOPE LIMITS: the agent is ammonium lactate (the neutralised salt), not free lactic acid at low pH; healthy skin, not xerotic or photoaged; two weeks only; n=20.Funding / interest: No conflict statement in the PubMed record. Author R. Thieroff-Ekerdt has an affiliation pattern consistent with pharmaceutical-industry involvement, and urea/ammonium lactate products are commercial; this could not be verified from the accessible record and is flagged rather than asserted.
  12. Usuki A, Ohashi A, Sato H, Ochiai Y, Ichihashi M, Funasaka Y. The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells. Exp Dermatol. 2003;12 Suppl 2:43-50. PMID 14756523.In vitroTier 3Supports: IN-VITRO ONLY — mouse B16 and human melanoma cell lines. NOT human skin, NOT patients. Glycolic acid or lactic acid at 300 or 500 microg/ml "inhibited melanin formation in similar dose-dependent manner, without affecting cell growth." Note the phrase 'similar dose-dependent manner' — the two acids behaved comparably; this paper does NOT show lactic acid is superior to glycolic acid on pigment. mRNA and protein expression and molecular size of tyrosinase, TRP-1 and TRP-2 were unaffected, but tyrosinase ACTIVITY was inhibited. Using human tyrosinase purified from the melanosome-rich large granule fraction, both acids "inhibit tyrosinase enzyme activity directly, but this effect was not due to the acidity of GA or LA, because adjusting the pH to 5.6 (the pH of GA and LA at concentrations of 2500 microg/ml), did not affect tyrosinase activity." Authors' careful framing: the acids "might work on pigmentary lesions not only by accelerating the turnover of the epidermis but also by directly inhibiting melanin formation in melanocytes." SCOPE LIMITS: melanoma cell lines are not normal melanocytes; concentrations are in-vitro culture doses with no established relationship to what reaches a melanocyte from a topical or peel application; the paper appears in a supplement issue. Any clinical depigmenting claim built on this is an inference, not a demonstrated human effect.Funding / interest: No conflict statement in the PubMed record. Kobe University Graduate School of Medicine academic authors. Supplement-issue publication; supplements are sometimes industry-sponsored, which could not be verified.
  13. Sarkar R, Lakhani R. Chemical Peels for Melasma: A Systematic Review. Dermatol Surg. 2024 Jul 1;50(7):656-661. PMID 38530985.Tier 1Supports: Systematic review of PubMed-indexed prospective case series of more than 10 cases and RCTs on chemical peels in melasma. Twenty-four studies included: 9 clinical/comparative trials and 15 RCTs, total sample size 1,075, study duration 8 to 36 weeks, only 8 split-face. All used self-assessment, physician global assessment and MASI. KEY CONCLUSION verbatim: "Glycolic acid was found to be the most safe and effective in melasma." Overall: "Chemical peels were found to be safe and effective in the management of melasma." CRITICAL SCOPE LIMIT stated by the authors: "A meta-analysis could not be done due to the heterogeneity of data" — so this is a narrative synthesis of the evidence base, and the ranking of glycolic acid as most safe and effective is a qualitative judgement, not a pooled quantitative estimate. Lactic acid is not singled out for a separate efficacy statement in the abstract.Funding / interest: No conflict statement in the accessible record. Lady Hardinge Medical College, New Delhi. Note: senior author Sarkar also authored the 2024 Dermatol Clin narrative review on the same topic, so these are not independent expert voices.
  14. Dorgham NA, Hegazy RA, Sharobim AK, Dorgham DA. Efficacy and tolerability of chemical peeling as a single agent for melasma in dark-skinned patients: A systematic review and meta-analysis of comparative trials. J Cosmet Dermatol. 2020 Nov;19(11):2812-2819. PMID 32947652.Tier 1Supports: The best available quantitative synthesis specifically in DARKER SKIN TYPES — directly relevant to the higher-phototype question. Ten RCTs and three prospective comparative studies, 478 patients. POOLED ESTIMATES: glycolic acid favoured over trichloroacetic acid on MASI (mean difference -1.89, 95% CI -3.26 to -0.52, P = .007). Glycolic acid NOT favoured over tretinoin (MD 0.53, 95% CI -0.46 to 1.52, P = .3), vitamin C iontophoresis (MD 1.50, 95% CI -0.50 to 3.50, P = .14), or amino fruit acid (MD 0.39, 95% CI -0.64 to 1.42, P = .46). TCA favoured over topical hydroquinone (MD -5.30, 95% CI -6.41 to -4.19, P < .001) and Jessner's solution favoured over hydroquinone (MD -3.20, 95% CI -5.35 to -1.05, P = .004). CONCLUSION: "chemical peelings are effective as single agents for management of melasma in patients with darker skin types, with the use of topicals as maintenance treatment." HONEST NEGATIVE, ABOUT THE EVIDENCE: lactic acid does NOT appear in any of the pooled comparisons reported. Despite lactic acid being widely promoted as the peel of choice for darker skin, it did not enter the meta-analytic estimates in the one meta-analysis dedicated to darker skin. Jessner's solution — which contains 14% lactic acid — does appear, but its effect cannot be attributed to the lactic acid component given the co-formulated salicylic acid and resorcinol.Funding / interest: No conflict statement in the accessible record. Cairo University and National Research Center, Egypt.
  15. Kornhauser A, Coelho SG, Hearing VJ. Applications of hydroxy acids: classification, mechanisms, and photoactivity. Clin Cosmet Investig Dermatol. 2010 Nov 24;3:135-42. PMID 21437068; PMCID PMC3047947.Tier 4Supports: A NARRATIVE review (not systematic — tier 4) covering alpha-hydroxy, beta-hydroxy, polyhydroxy and bionic acids. Used here for two things, one positive and one negative. POSITIVE: on UV sensitivity it states "glycolic acid (10%) increased the SSR sensitivity of human skin, whereas SA (2%) did not", while noting "The photosensitizing effects of glycolic acid were small." It also relays the Usuki finding that "glycolic acid and lactic acid (300-500 microg/mL) suppressed melanin formation by directly inhibiting tyrosinase activity in human and mouse melanoma cells." NEGATIVE, and directly load-bearing for this entry: on reading the full text for molecular-weight-driven penetration, the review does NOT discuss how molecular weight or molecular size affects hydroxy acid skin penetration, and makes NO comparison between glycolic and lactic acid penetration. The only penetration mechanism it discusses is lipophilicity for a different compound: "betaLHA has an eight-carbon fatty chain linked to the benzene ring making it more lipophilic than SA. This may account for its slower skin penetration." The review also does not discuss lactic acid as an NMF component. The authors concede that despite the large literature, hydroxy acid "biological mechanism(s) of action still require more clarification", and emphasise "the important contribution of cosmetic vehicles in these types of studies".Funding / interest: Lead author Kornhauser is listed as "US Food and Drug Administration [retired]"; Coelho and Hearing are NIH. No commercial funding declared — one of the few genuinely non-industry sources in this package.
  16. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation response. GOV.UK, updated 7 August 2025.Tier 1Supports: The authoritative statement of the England position, fetched and read directly. Over 11,800 consultation responses, majority agreeing with the proposals. The proposed model is a three-tier green/amber/red system: green = lower-risk, performable by non-healthcare professionals meeting training standards; amber = medium risk, requiring licensing plus oversight by a named regulated healthcare professional with an accredited qualification to prescribe, administer and supervise; red = highest risk, outside the licensing scheme and brought into CQC regulation. CRITICAL FOR ACCURACY: individual procedures have NOT been assigned to tiers. Verbatim: "further work is required to determine where specific procedures will sit in the proposed tiering system" and "initial work in this area will prioritise the introduction of regulations for the highest-risk procedures, and we will develop proposals which will be consulted on early next year." ON PEELS SPECIFICALLY: the consultation proposed that "laser and chemical peel procedures sit across different categories" based on strength and depth of penetration — a proposal only. STATUS: not in force; requires secondary legislation. Verbatim: "this work will be subject to further public consultations to inform a finalised design for the licensing scheme, which will be subject to Parliamentary debate before implementation." Chemical peels are otherwise mentioned only in satisfaction data. Some respondents argued there should be no amber category at all.
  17. Joint Council for Cosmetic Practitioners. Treatments (public information page), listing recognised procedural modalities and associated CPSA standards. Accessed 1 August 2026.Tier 4Supports: Establishes where chemical peels sit in UK voluntary regulation. The JCCP recognises exactly five procedural modalities: (1) Botulinum Toxins, (2) Dermal Fillers, (3) Skin Rejuvenation - Micro Needling and Peels, (4) Lasers and Light (LIPLED), (5) Hair Restoration Surgery. Chemical peels, including lactic acid peels, fall within modality 3, governed by the corresponding CPSA Standard. Practitioners must be "qualified at the appropriate educational level" for each modality they register for. SCOPE LIMITS, important for UK accuracy: the JCCP register is VOLUNTARY, not statutory — it carries no legal force and does not license anyone. The page gives no lactic-acid-specific concentration limits and no phototype-specific guidance. Separately reported: 689 registrants as at 1 January 2023, i.e. a small fraction of UK practitioners.

Continue learning with MSTA#

Skinipedia is written by the educators at MSTA, the medic-led skincare training academy in Liverpool.